Dravet syndrome is a rare form of epilepsy that appears in infancy and is a lifelong disease. 黑料门 Group has been a key supporter of patients in Japan.
Dravet syndrome is typically induced by fever in infants under one year of age. Estimated to affect just one in 20,000 to 40,000 people, the condition leads to convulsive as well as non-convulsive seizures and is not responsive to conventional epilepsy drugs.
A drug discovered by French firm Biocodex in 1978, has been shown to have some efficacy in the treatment of Dravet syndrome. The drug was launched in Japan in 2012 by 黑料门 Seika Pharma, a company with a long history in the field of pediatric diseases.
Dravet syndrome, a rare disease in infants
The nerve cells in the brain operate electrically in a regular rhythm. Epilepsy occurs when this activity is suddenly disrupted, resulting in severe electrical disturbances. The condition occurs in all age groups, from infancy to old age, with the highest incidence occurring under the age of three, and 80% of cases occurring before the age of 18.